Telavancin (Theravance)

Curr Opin Investig Drugs. 2005 Feb;6(2):216-25.

Abstract

Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram-positive bacterial infection. Phase III trials in complicated skin and skin structure infections commenced in September 2004.

Publication types

  • Review

MeSH terms

  • Aminoglycosides / adverse effects
  • Aminoglycosides / chemical synthesis
  • Aminoglycosides / metabolism
  • Aminoglycosides / pharmacokinetics
  • Aminoglycosides / pharmacology*
  • Aminoglycosides / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Contraindications
  • Drug Evaluation, Preclinical
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology
  • Lipoglycopeptides
  • Structure-Activity Relationship

Substances

  • Aminoglycosides
  • Lipoglycopeptides
  • telavancin